- ￥5280.90
- 阿拉丁
- 上海
- A655899
- 2026年01月06日
企业认证
相关产品推荐更多 >
SGC-iMLLT，2255338-25-9，10mM in DMSO，阿拉丁
￥1100.90
Lansoprazole sulfide-d4，1216682-38-0，≥99%，阿拉丁
￥2500.90![2(R)-[[4-(piperidin-1-yl)piperidin-1-yl]carbonylmethyl]-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-1-yl]acetic acid N-[(R)-alpha-methyl-3-trifluoromethylbenzyl]amide，阿拉丁](https://img1.dxycdn.com/p/s14/2026/0106/339/0489526365276948002.jpg!wh200)
2(R)-[[4-(piperidin-1-yl)piperidin-1-yl]carbonylmethyl]-2-[3(S)-(4(S)-phenyloxazolidin-2-on-3-yl)-4(R)-(2-styryl)azetidin-2-on-1-yl]acetic acid N-[(R)-alpha-methyl-3-trifluoromethylbenzyl]amide，阿拉丁
￥2999.90
MRS8054，Moligand™，阿拉丁
￥3999.90
Belvarafenib (HM95573)，1446113-23-0，Moligand™, ≥98%，阿拉丁
￥1162.90
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
避光;干燥;-80℃储存
- 英文名：
ADRA1D receptor antagonist 1
- 库存：
期货
- 供应商：
上海阿拉丁生化科技股份有限公司
- CAS号：
1191908-14-1
- 规格：
A655899-1ml
英文名：ADRA1D receptor antagonist 1
纯度或规格：10mM in DMSO
SPU：A655899
CAS：1191908-14-1
存储温度：避光;干燥;-80℃储存
运输条件：特低温运输
查看阿拉丁官网此产品相关对应页面：
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Characterization of Nuclear Receptor Ligands by Multiplexed Peptide Interactions
, although described for nuclear receptors, may also be applied to other types of molecular interactions. Keywords: Microsphere; flow cytometry; nuclear receptor; coactivator; corepressor; cofactor; agonist; antagonist; ligand; ligand binding
Characterization of Neurotensin Receptors
either radiolabeled neurotensin or SR 48692 (a nonpeptide neurotensin antagonist) as radioligands are described. These procedures may be used to screen selective ligands at neurotensin receptor subtypes. Keywords: neurotensin; SR 48692
Radioligand Binding Assays for the Glycine Site on N‐Methyl‐D‐Aspartate Receptors
., Fadayel, G.M., Taylor, V.L., Murawsky, M.K., Nyce, P., and Salituro, F.G.. 1997. Pharmacological characterization of MDL‐105,519, an NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 323:181‐192.
技术资料暂无技术资料 索取技术资料
